What is the expected growth rate for BIOSPIN, CALID, and BEST for the full year, taking into account the acquisitions and the impact of the tariff decision announced today 
. Obviously that's been traumatic [Sp] throughout this earnings season, so could you just talk a little bit about your expectations for NANO and also for China? And given the tariff decision announced today, has that been any [Inaudible]?
Frank Laukien -- President and Chief Executive Officer
Yes. So yes, if you take it all in for the full year, NANO is going to grow a little bit more slowly. Organically at least. They had some acquisitions, very good acquisitions.
But organically, it's going to grow more slowly than we had anticipated at the beginning of the year. On the other hand, BIOSPIN has stepped up. CALID has continued to do very well. And also notably, BEST has stepped up compared to our expectations at the beginning of the year, which all in, as you've seen, we're comfortable with our annual guidance.
So NANO also has some emerging life science drivers. We think it's semiconductor business could conceivably recover in 2020, possibly before an industrial recovery. So there's different drivers under the hood at NANO that -- and oh, most importantly, most of the Bruker NANO spending is also academic government, which you know, even in a downturn, tends to be very resilient and still shows some, at least modest growth. But NANO is there's more economic uncertainty for sure, and a lot of that comes from China or some of the economies that export into China quite a bit.
And they are the industrial spending -- industrial spending patterns seem to be not surprisingly to us and compare to also what we've seen from any other companies are becoming -- appear to becoming weaker, and we see some of that as well. There's more uncertainty in China. Even when we get orders, sometimes until we have letters of credit and end user certificate and other paperwork, everything seems to be moving a little bit more slowly, and that's not unexpected from our perspective either. And it probably confirms what you've heard elsewhere, at least from some some that have reported recently.
Tycho Peterson -- J.P. Morgan -- Analyst
OK, and then a follow up for Gerald, just on free cash flow. It was a pretty significant step down. Obviously you have the inventory build up dynamic that you have [Inaudible] can you just talk a little bit about you know where are we in the inventory build cycle and how should we think about free cash flow potentially recovering, if at all, in the back half of the year?
Gerald Herman -- Chief Financial Officer
Yes. I'd say, as you already know, I think our free cash flow fluctuates quite considerably quarter to quarter. We have a build up here relative to our Penang facility, as well as our gigahertz NMR activity. We also had a little bit of delayed shipments in the quarter, which drove collections and receivables to a different place.
We also have a bit of a pickup, as I think we commented on in the past for the year in CAPEX, so those are all factors. So I do expect this fluctuation to continue from a quarter-to-quarter perspective, but I would also say we do have more activity from a revenue perspective and certainly from a profitability perspective in the latter half of the year. So we're not expecting any major change from our previous view on free cash flow going forward.
Frank Laukien -- President and Chief Executive Officer
What that means, if I may expand, since we had negative free cash flow in the first half of the year, while we don't guide on this quarterly, we expect to have -- to come back to your specific question, Tycho, I think we're probably at the peak of the inventory buildup or at least very close to it. So we would expect positive free cash flow in the second half of the year.
Tycho Peterson -- J.P. Morgan -- Analyst
OK, thank you.
Operator
Our next question comes from Puneet Souda from SVB Leerink. Please go ahead with your question.
Puneet Souda -- SVB Leerink -- Analyst
Yes, hi, Frank. Thanks. And on the quarter, just help me understand on Project Accelerate if you could. You obviously had a good set of growth here for the last couple of quarters, and now you're above -- the growth is above
. Obviously that's been traumatic [Sp] throughout this earnings season, so could you just talk a little bit about your expectations for NANO and also for China? And given the tariff decision announced today, has that been any [Inaudible]?
Frank Laukien -- President and Chief Executive Officer
Yes. So yes, if you take it all in for the full year, NANO is going to grow a little bit more slowly. Organically at least. They had some acquisitions, very good acquisitions.
But organically, it's going to grow more slowly than we had anticipated at the beginning of the year. On the other hand, BIOSPIN has stepped up. CALID has continued to do very well. And also notably, BEST has stepped up compared to our expectations at the beginning of the year, which all in, as you've seen, we're comfortable with our annual guidance.
So NANO also has some emerging life science drivers. We think it's semiconductor business could conceivably recover in 2020, possibly before an industrial recovery. So there's different drivers under the hood at NANO that -- and oh, most importantly, most of the Bruker NANO spending is also academic government, which you know, even in a downturn, tends to be very resilient and still shows some, at least modest growth. But NANO is there's more economic uncertainty for sure, and a lot of that comes from China or some of the economies that export into China quite a bit.
And they are the industrial spending -- industrial spending patterns seem to be not surprisingly to us and compare to also what we've seen from any other companies are becoming -- appear to becoming weaker, and we see some of that as well. There's more uncertainty in China. Even when we get orders, sometimes until we have letters of credit and end user certificate and other paperwork, everything seems to be moving a little bit more slowly, and that's not unexpected from our perspective either. And it probably confirms what you've heard elsewhere, at least from some some that have reported recently.
Tycho Peterson -- J.P. Morgan -- Analyst
OK, and then a follow up for Gerald, just on free cash flow. It was a pretty significant step down. Obviously you have the inventory build up dynamic that you have [Inaudible] can you just talk a little bit about you know where are we in the inventory build cycle and how should we think about free cash flow potentially recovering, if at all, in the back half of the year?
 Gerald Herman -- Chief Financial Officer
Yes. I'd say, as you already know, I think our free cash flow fluctuates quite considerably quarter to quarter. We have a build up here relative to our Penang facility, as well as our gigahertz NMR activity. We also had a little bit of delayed shipments in the quarter, which drove collections and receivables to a different place.
We also have a bit of a pickup, as I think we commented on in the past for the year in CAPEX, so those are all factors. So I do expect this fluctuation to continue from a quarter-to-quarter perspective, but I would also say we do have more activity from a revenue perspective and certainly from a profitability perspective in the latter half of the year. So we're not expecting any major change from our previous view on free cash flow going forward.
Frank Laukien -- President and Chief Executive Officer
What that means, if I may expand, since we had negative free cash flow in the first half of the year, while we don't guide on this quarterly, we expect to have -- to come back to your specific question, Tycho, I think we're probably at the peak of the inventory buildup or at least very close to it. So we would expect positive free cash flow in the second half of the year.
Tycho Peterson -- J.P. Morgan -- Analyst
OK, thank you.
Operator
Our next question comes from Puneet Souda from SVB Leerink. Please go ahead with your question.
Puneet Souda -- SVB Leerink -- Analyst
Yes, hi, Frank. Thanks. And on the quarter, just help me understand on Project Accelerate if you could. You obviously had a good set of growth here for the last couple of quarters, and now you're above -- the growth is above